A novel series of indolebutyric acids with varying benzoyl substituents were synthesized to develop nonsteroidal inhibitors of steroid 5a a-reductase. We previously reported the discovery of a novel nonsteroidal 5a a-reductase inhibitor, FR119680, which had an IC 50 value of 5.0 nM against the rat prostatic enzyme. However, this compound was not strongly active against the human prostatic enzyme. By further study of the structure-activity relationships we succeeded in producing the strongly active compound, FK143, 4-[3-[3-[bis(4-isobutylphenyl)-methylamino]benzoyl]-1H-indol-1-yl]butyric acid, with an IC 50 value of 1.9 nM against the human enzyme. FK143 also has in vivo inhibitory activity against the castrated young rat model and it should therefore be an extremely useful agent for the treatment of benign prostatic hyperplasia.
Steroid 5a-reductase enzymatically converts testosterone (T) into 5a-dihydrotestosterone (DHT), which is the most active agonist for androgen receptors. 4) An accumulation of DHT to high levels in the prostate gland or the skin is recognised as leading to various pathological conditions such as benign prostatic hyperplasia (BPH), acne, female hirsutism, and male pattern baldness. 5) Therefore, therapy with a 5a-reductase inhibitor would be expected to lead to a decrease in DHT concentration within the prostate gland or other tissues, and may be an extremely useful agent for treatment of BPH and other diseases.
Though many laboratories have investigated 5a-reductase inhibitors, 6,7) these efforts have predominantly concentrated on compounds with a steroidal structure, for example finasteride 6a) (Table 3 ). However, due to the presence of a steroidal structure, there is the strong possibility of unwanted side-effects. 8) We previously reported 1) the discovery of an excellent nonsteroidal prototype compound, FR119680 ( Fig.  1) , which displays high in vitro inhibitory activity against rat prostatic 5a-reductase (IC 50 ϭ5.0 nM) and in vivo inhibitory activity against the castrated young rat model. 9) However, further investigation of FR119680 revealed that it had only weak in vitro inhibitory activity against the human prostatic enzyme (IC 50 ϭ1.6 mM). Other derivatives based on the indole nucleus also did not have potent inhibitory activities against the human enzyme, thus, further modification was necessary.
A nonsteroidal inhibitor, ONO-3805, was reported in a patent by Nakai et al. 7b) This compound displayed about three times stronger inhibitory activity against the human enzyme (IC 50 ϭ0.53 mM) than FR119080. The structures of FR119080 and ONO-3805 are quite different, however, there are some similarities in these two compounds. Both possess a carboxylic acid residue and a diaryl ether substituent at the same distance from the benzene ring of the corresponding nucleus. Therefore, we decided to introduce the same benzoyl substituent present in ONO-3805 to indole-3-butyric acid. The resulting compound 1 displayed stronger inhibitory activity against the human enzyme (IC 50 ϭ0.32 mM) than both FR119080 and ONO-3805. Thus, further modifications were then made to the N-benzoyl substituent of 1 to improve this activity further.
Results and Discussion Synthesis of Indole Derivatives
Most N-benzoyl indole derivatives were synthesized by reaction of a phenyl ester of the benzoic acid and a dianion of indole-3-butyric acid, which was prepared from the corresponding carboxylic acid and sodium hydride in N,N-dimethylformamide (DMF) (Chart 1).
Modification of the N-Benzoyl Group The prepared compounds were evaluated for their ability to inhibit human prostatic 5a-reductase, and inhibitory activity was expressed as the IC 50 value.
ONO-3805 was a racemic mixture due to the asymmetric center in the benzoyl substituent. Since racemic mixtures often cause trouble in development, we introduced achiral benzoyl substituents onto the indole nucleus. Several derivatives containing diaryl substituents were prepared from indole-3-butyric acid, examples of which are shown in Table 1 (2-6). Amongst them, the compound with a m-phenoxymethylbenzoyl substituent (4) had the strongest inhibitory activity: (IC 50 ϭ0.40 mM). Thus, further modifications were con- hibitory activity ( Table 2) . One of the differences in the structures of these compounds is the presence of methyl groups on the benzoyl substituent; that is 1 has two methyl groups in the benzoyl group and one methyl group on the carbon atom of the ether linker moiety. Thus, two methyl groups were introduced to the benzoyl group of 12, however, the resulting compound 17 still displayed no significant in vivo inhibitory activity (Table 2) . Since the introduction of methyl groups to the benzene ring did not improve in vivo inhibitory activity, other modifications were examined. In order to avoid creation of an asymmetric center, a 4-isobutylphenyl group was introduced to the carbon atom of the ether bond instead of the methyl group; that is a bis(4-isobutylphenyl)methoxy group was introduced to the benzoyl group in the para and meta positions (18, 19). The meta substituted compound 19 had strong in vitro inhibitory activity (IC 50 ϭ56 nM), however, it did not have any significant in vivo inhibitory activity.
Next we examined modification of the oxygen atom of the diphenylmethyloxy group of 19 by replacement with a sulfur April 1999 483 Chart 2 atom, CH 2 group and NH group (20-22). Amongst these compounds 22 had the strongest in vitro inhibitory activity (IC 50 ϭ38 nM), and also significant in vivo inhibitory activity at 10 mg/kg ( p.o.).
22 displayed significant inhibitory activities both in vitro and in vivo, but did not show completely satisfactory in vitro inhibitory activity. In order to improve activity, further modifications were then examined. Several groups were introduced onto the indole nucleus of 22; e.g. chloro (23) and methyl (24). However, these changes weakened human in vitro inhibitory activities. Interestingly, when we exchanged the positions of the two indole substituents of 22, we obtained the best compound, FK143, which displayed ten times stronger in vitro inhibitory activity than 22. FK143 had extremely strong inhibitory activity both in vitro and in vivo; its IC 50 value was 1.9 nM against the human enzyme and it displayed strong in vivo inhibitory activity against the castrated young rat model at 10 mg/kg ( p.o.).
Synthesis of FK143 FK143 was prepared as shown in Chart 2. The 3-benzoyl compound (25) was obtained by Friedel-Crafts reaction between indole and 3-nitrobenzoyl chloride; and N-alkylation of 25 was then achieved using ethyl 4-bromobutanoate and Hünig's base. The nitro group was converted to an amino group by catalytic hydrogenation and the diphenylmethyl was introduced to the amino group using bis(4-isobutylphenyl)methyl chloride and Hünig's base. The ester (28) was saponificated with 1 N sodium hydroxide to afford FK143.
Conclusions
We set out to produce 5a-reductase inhibitors with a nonsteroidal structure beginning with the indole nucleus of FR119080. By introducing a benzoyl substituent with a diphenylmethyl group and changing the positions of the substituents we have succeeded in producing the strongly active compound, FK143, which displays high in vitro inhibitory activity against human prostatic 5a-reductase 10) and, significantly, in vivo inhibitory activity against the castrated young rat model. 9) FK143 therefore has great potential to be an extremely useful agent for the treatment of BPH.
Experimental
Chemistry Melting points were determined on a Thomas Hoover melting point apparatus and are uncorrected. Infrared (IR) spectra were obtained on a Perkin Elmer 16PC fourier transform (FT) IR spectrometer. Proton magnetic resonance ( 1 H-NMR) spectra were obtained on a Bruker AM200 (200 MHz) spectrometer or a Varian Gemini-300 (300 MHz) spectrometer, and chemical shifts are reported in parts per million relative to tetramethyl silane (TMS) as internal standard (TMS, d: 0.00). Mass spectra (MS) were obtained on a VG Platform. A mixture of 1a (8.0 g, 40 mmol), 1-(4-isobutylphenyl)ethyl bromide (8.0 g, 33 mmol) and K 2 CO 3 (11.58 g, 84 mmol) in DMF (130 ml) was stirred at 20°C for 5.5 h. The reaction mixture was then poured into a mixture of water and EtOAc, and the organic layer was separated, washed with water and brine, and dried over MgSO 4 . After evaporation of solvent, the residue was purified by silica gel column chromatography (CHCl 3 ) to give 4-bromo-2,3-dimethylphenyl 1-(4-isobutylphenyl)ethyl ether (1b) (9. To a solution of DMF (0.79 g, 18.8 mmol) in CH 2 Cl 2 (30 ml) was added (COCl) 2 (5 ml). After stirring at 20°C for 2 h, the reaction mixture was concentrated in vacuo. The residue was redissolved in CH 2 Cl 2 (50 ml) and cooled to Ϫ45°C, and a solution of 1c (2.36 g, 7.2 mmol) in CH 2 Cl 2 (20 ml) was added. After stirring at Ϫ45°C for 2.5 h, the reaction mixture was added to a THF solution of sodium phenolate, which was prepared from NaH (60% dispersion in mineral oil; 1.44 g, 36 mmol) and phenol (3.39 g, 36 mmol) in THF (35 ml). After stirring at Ϫ45°C for 30 min, the reaction mixture was poured into a mixture of 1 N HCl and EtOAc. The organic layer was separated, washed with water and brine and dried over MgSO 4 Method A: A solution of 1H-indole-3-butyric acid (1.35 g, 6.65 mmol) in DMF (20 ml) was added to a suspension of NaH (60% dispersion in mineral oil; 0.80 g, 20 mmol) in DMF (30 ml) at Ϫ45°C, and the reaction mixture was allowed to warm up to 0°C. After stirring at 0°C for 15 min, the reaction mixture was cooled to Ϫ20°C, and a solution of 1d (2.62 g, 6.52 mmol) in DMF (20 ml) was added. After stirring at Ϫ20°C for 30 min, the reaction mixture was poured into chilled 1 N HCl. The mixture was extracted with EtOAc, and the extract washed with water and brine, and dried over MgSO 4 
4-[1-[4-(4-Isobutylbenzyloxy)benzoyl]-1H-indol-3-yl]butyric Acid (2)
A mixture of methyl 4-hydroxybenzoate (1.52 g, 10 mmol), 4-isobutylbenzyl chloride (2.0 g, 11 mmol) and K 2 CO 3 (3.0 g, 22 mmol) in DMF (10 ml) was stirred at 50°C for 6 h. The reaction mixture was poured into a mixture of 1 N HCl and EtOAc. The organic layer was separated, washed with water and brine, and dried over MgSO 4 . After evaporation of solvent, the residue was crystallized (hexane) to give methyl 4-(4-isobutylbenzyloxy)benzoate (2a) ( To a solution of 2a (1.9 g, 6.4 mmol) in 1,4-dioxane (10 ml) was added 1 N NaOH (10 ml, 10 mmol), and the mixture was stirred at 20°C for 3 h. After acidification with 1 N HCl, the mixture was extracted with EtOAc. The extract was washed with water and brine, and dried over MgSO 4 . After evaporation of solvent, the residue was crystallized (hexane) to give 4-(4-isobutylbenzyloxy)benzoic acid (2b) (1.78 g, 98.3%) as a white solid. To a solution of 2b (1.71 g, 6.0 mmol) in CH 2 Cl 2 (30 ml) were added (COCl) 2 (0.6 ml, 6.8 mmol) and DMF (0.05 ml). After stirring at 20°C for 2 h, the mixture was concentrated in vacuo. The residue was dissolved in THF (15 ml) and the solution was added to a solution of sodium phenolate, prepared from NaH (60% dispersion in mineral oil; 0.72 g, 18 mmol) and phenol (1.69 g, 18 mmol) in THF (17 ml). After stirring at 20°C for 15 min, the mixture was poured into a mixture of 1 N HCl and EtOAc. The organic layer was separated, washed with water and brine, and dried over MgSO 4 . After evaporation of solvent, the residue was crystallized (diisopropyl ether (IPE)) to give phenyl 4-(4-isobutylbenzyloxy)benzoate (2c) (1.83 g, 84.7%) as a white solid. 
4-[1-[3-(4-Isobutylphenoxymethyl)benzoyl]-1H-indol-3-yl]butyric Acid (4)
A mixture of 4-isobutylphenol (1.0 g, 6.66 mmol), methyl 3-(bromomethyl)benzoate (1.52 g, 6.66 mmol) and K 2 CO 3 (1.84 g, 13.2 mmol) in DMF (20 ml) was stirred at 20°C overnight. The reaction mixture was partitioned between Et 2 O and 1 N HCl, and the organic layer washed with water and brine then dried over MgSO 4 . After evaporation of solvent, the residue was purified by silica gel column chromatography (10% EtOAc in hexane) to give methyl 3-(4-isobutylphenoxymethyl)benzoate (4a) 
4-[1-[3-[N-(4-Isobutylphenyl)-N-methylaminomethyl]benzoyl]-1H-indol-3-yl]butyric Acid (5)
A mixture of 4-isobutyl-N-methylaniline (1.3 g, 7.96 mmol), methyl 3-bromomethylbenzoate (2.01 g, 8.76 mmol) and iPr 2 NEt (2.77 ml, 15.9 mmol) in CH 2 Cl 2 (20 ml) was stirred at 20°C for 3 h. The reaction mixture was then partitioned betweeen EtOAc and water, and the organic layer washed with water and brine, and dried over MgSO 4 . Evaporation of solvent gave crude methyl 3-[N-(4-isobutylphenyl)-N-methylaminomethyl]benzoate (5a) (2.70 g) as a pale yellow oil, which was used for the next step without further purification. To a solution of crude 5a (2.6 g) in THF (30 ml) were added 1 N NaOH (16.7 ml) and MeOH (15 ml). The reaction mixture was stirred at 20°C for 4 h and organic solvent removed by evaporation. The aqueous layer was then acidified with 1 N HCl and extracted with EtOAc. The extract was washed with water and brine, dried over MgSO 4 
4-[1-[3-[2-(4-Isobutylphenyl)ethyl]benzoyl]-1H-indol-3-yl]butyric
Acid (6) Following the procedure described above for 3b, (E )-3-cyano-4Ј-isobutylstilbene (6a) (995 mg, 43.3%) was prepared from 4-isobutylbenzyltriphenylphosphonium chloride (4.7 g) and 3-cyanobenzaldehyde (1.15 g). A solution of 6a (875 mg, 3.35 mmol) in a mixture of 3 N HCl (15 ml) and formic acid (50 ml) was heated under reflux with stirring for 3 d. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc. The extract was washed with water and brine and dried over MgSO 4 . After evaporation of solvent, the residue was recrystallized (IPE) to give (E )-4Ј-isobutylstilbene-3-carboxylic acid (6b) (512 mg, 54.5%) as colorless crystals. Following the procedure described above for 2c, phenyl (E )-4Ј-isobutylstilbene-3-carboxylate (6c) (419 mg, 79.2%) was prepared from 5b (416 mg). 
4-[1-[3-(4-tert-Butylphenoxymethyl)benzoyl]-1H-indol-3-yl]butyric
Acid (9) Following the procedure described above for 4a, methyl 3-(4-tertbutylphenoxymethyl)benzoate (9a) (3.23 g, 108.2%) was obtained from 4-tert-butylphenol (1.5 g) and methyl 3-(bromomethyl)benzoate (2.29 g) as an oil, which was used for the next step without further purification. 1 
4-[1-[3-[4-(2-Methyl-2-propenyl)phenoxymethyl]benzoyl]-1H-indol-3-yl]butyric
Acid (10) A 1.6 M solution of BuLi in hexane (6.9 ml, 11.1 mmol) was added to a suspension of isopropyltriphenylphosphonium iodide (4.8 g, 11.1 mmol) in THF (100 ml) at 0°C, and the mixture was stirred at 20°C for 2 h. The reaction mixture was cooled to 0°C and a solution of methyl 3-(4-formylphenoxymethyl)benzoate (2.0 g, 7.40 mmol) in THF (10 ml) was added. After stirring at 0°C for 1 h, the reaction mixture was partitioned between ether and 1 N HCl. The organic layer was washed with water and brine, dried over MgSO 4 , and evaporated in vacuo. The residue was purified by silica gel column chromatography (EtOAc : hexaneϭ 1 : 5) to give methyl 3-[4-(2-methyl-2-propenyl)phenoxymethyl]benzoate (10a) (1.02 g, 46.5%) as an oil. 1H, d, Jϭ1 Hz), 8.37 (1H, dd, Jϭ1, 8 
Hz). ESI-MS m/z: 480 (MϪH)
Ϫ .
4-[1-[3-(3-Isobutylphenoxymethyl)benzoyl]-1H-indol-3-yl]butyric
Acid (12) Following the procedure described above for 4a, methyl 3-(3-formylphenoxymethyl)benzoate (12a) (3.15 g, 89.0%) was prepared from 3-hydroxybenzaldehyde (1.6 g) and methyl 3-(bromomethyl)benzoate (3.0 g). Following the procedure described above for 2c, phenyl 3-(3-isobutylphenoxymethyl)benzoate (12e) (2.15 g, 97.0%) was prepared from 12d (1.75 g). 
4-[1-[3-(2-Isobutylphenoxymethyl)benzoyl]-1H-indol-3-yl]butyric
Acid (13) Following the procedure described above for 4a, methyl 3-(2-formylphenoxymethyl)benzoate (13a) (2.76 g, 77.8%) was prepared from 2-hydroxybenzaldehyde (1.6 g) and methyl 3-(bromomethyl)benzoate (3.0 g). Following the procedure described above for 10a, methyl 3-[2-(2-methyl-1-propenyl)phenoxymethyl]benzoate (13b) (2.17 g, 73.3%) was prepared from 13a (2.70 g) and isopropyltriphenylphosphonium iodide (6.48 g). 13b (2.14 g) was hydrogenated over 5% Pd-C (600 mg) under H 2 (3 atm) to give methyl 3-(2-isobutylphenoxymethyl)benzoate (13c) (1.99 g, 92.6%) as an oil. Following the procedure described above for 5b, 13c (1.97 g) was hydrolyzed with 1 N NaOH to give 3-(2-isobutylphenoxymethyl)benzoic acid (13d) (1.42 g, 75.7%) as colorless crystals. Following the procedure described above for 2c, phenyl 3-(2-isobutylphenoxymethyl)benzoate (13e) (1.66 g, 93.5%) was prepared from 13d (1.40 g). 
4-[1-[3-[3-(Isopropyloxy)phenoxymethyl]benzoyl]-1H-indol-3-yl]butyric Acid (14)
Following the procedure described above for 4a, methyl 3-[3-(isopropyloxy)phenoxymethyl]benzoate (14a) (2.15 g, 78.4%) was prepared from 3-(isopropyloxy)phenol (1.39 g) and methyl 3-(bromomethyl)-benzoate (2.09 g) as an oil. 1H, br s) .
Following the procedure described above for 4b, 14a (2.14 g) was hydrolyzed with 1 N NaOH to give 3-[3-(isopropyloxy)phenoxymethyl]benzoic acid (14b) (1.79 g, 87.9%) as colorless crystals. (1H, br s) .
Following the procedure described above for 2c, phenyl 3-[3-(isopropyloxy)phenoxymethyl]benzoate (14c) (676 mg, 53.5%) was prepared from 14b (1.0 g) as a colorless oil. 
4-[1-[3-(3-Bromophenoxymethyl)benzoyl]-1H-indol-3-yl]butyric Acid
(16) Following the procedure described above for 4a, methyl 3-(3-bromophenoxymethyl)benzoate (16a) (2.25 g, 80.3%) was prepared from 3-bromophenol (1.51 g) and methyl 3-(bromomethyl)benzoate (2.0 g). Following the procedure described above for 5b, 16a (2.15 g) was hydrolyzed with 1 N NaOH to give 3-(3-bromophenoxymethyl)benzoic acid (16b) (1.64 g, 79.3%) as colorless crystals. Following the procedure described above for 2c, phenyl 3-(3-bromophenoxymethyl)benzoate (16c) (1.80 g) was prepared from 16b (1.5 
4-[1-[2,3-Dimethyl-5-(3-isobutylphenoxymethyl)benzoyl]-1H-indol-3-yl]butyric Acid (17)
To a solution of 3,4-dimethylbenzoic acid (10.0 g, 6.66 mmol) in acetic acid (300 ml) were added nitric acid (47 ml), water (33 ml) and bromine (11.7 g, 7. 33 mmol) at 20°C, followed by an aqueous solution (70 ml) of silver nitrate (14.7 g, 8.66 mmol) over 1 h. The reaction mixture was partitioned between EtOAc and water, and the organic layer was washed with water and brine, and dried over MgSO 4 . After evaporation of solvent, the residue was purified by recrystallization (EtOH) to give 3-bromo-4,5-dimethylbenzoic acid (17a) (6.16 g, 40.4%) as yellow crystals. Triphenylphosphine (7.23 g, 27.5 mmol) was added to a mixture of the alcohol 17b (3.95 g, 18.4 mmol) and CBr 4 (9.14 g , 27.5 mmol) in Et 2 O (100 ml) at 0°C. The reaction mixture was allowed to warm up to 20°C and stirred for 2 h. The precipitates were filtered off and the filtrate was washed with water and brine, and dried over MgSO 4 . After evaporation of solvent, the residue was purified by silica gel column chromatography (CHCl 3 ) to give 3-bromo-4,5-dimethylbenzyl bromide (17c) ( A mixture of 17d (2.00 g, 5.76 mmol), Mg (280 mg, 11.5 mmol) and 1,2-dibromoethane (540 mg, 2.88 mmol) in THF (20 ml) was stirred under reflux for 2 h, and cooled to 20°C. After addition of dry ice (2 g), the reaction mixture was poured into a mixture of Et 2 O and 1 N HCl. The organic layer was washed with water and brine, dried over MgSO 4 , and evaporated in vacuo. The residue was purified by recrystallization (EtOAc-hexane) to give 2,3-dimethyl-5-(3-isobutylphenoxymethyl)benzoic acid (17e) ( 18c (572 mg, 1.25 mmol) was dissolved in CF 3 CO 2 H (12 ml) and the mixture was stirred at 25°C for 15 min. After evaporation of solvent, the residue was dissolved in EtOAc, washed with aq. NaHCO 3 and brine, and dried over MgSO 4 . After evaporation of solvent, the residue was purified by silica gel column chromatography (EtOAc : hexaneϭ1 : 2) to give benzyl 4-[1-(4-hydroxybenzoyl)-1H-indol-3-yl]butyrate (18d) (350 mg, 67.7%) as a pale yellow oil. A solution of 18d (1.75 g, 4.23 mmol) in DMF (10 ml) was added to a suspension of NaH (60% dispersion in mineral oil, 203 mg, 5.08 mmol) in DMF (10 ml) at Ϫ40°C, and the mixture was stirred for 15 min. A solution of bromobis(4-isobutylphenyl)methane (1.68 g, 4.70 mmol) in DMF (10 ml) was added to the reaction mixture at Ϫ40°C, and the resulting mixture was allowed to warm up to 0°C. After stirring for 4 h at 0°C, the mixture was poured into chilled 1 N HCl, and extracted with EtOAc. The extract was washed with water and brine, and dried over MgSO 4 . After evaporation of solvent, the residue was purified by silica gel column chromatography 
4-[1-[3-[Bis(4-isobutylphenyl)methoxy]benzoyl]-1H-indol-3-yl)butyric
Acid (19) Following the procedure described above for 2c, phenyl 3-(methoxymethoxy)benzoate (19a) (3.17 g, 74.4%) was prepared from 3-(methoxymethoxy)benzoic acid (3.0 g). To a solution of 19b (1.4 g, 3.81 mmol) in 1,4-dioxane (10 ml) was added 4 N HCl in 1,4-dioxane (4 ml, 16.0 mmol) at 20°C. After stirring for 6 h, the reaction mixture was partitioned between ether and water. The organic layer was washed with water and brine, and dried over MgSO 4 . After evaporation of solvent, the residue was triturated with IPE to give 4-[1-(3-hydroxybenzoyl)-1H-indol-3-yl]butyric acid (19c) (1.0 g, 81.2%) as colorless crystals. (20) A mixture of 3-bromothiophenol (1.0 g, 5.29 mmol) , bromobis(4-isobutylphenyl)methane (2.0 g, 5.55 mmol) and K 2 CO 3 (1.46 g, 10.5 mmol) in DMF (10 ml) was stirred at 20°C for 1 h, and partitioned between EtOAc and water. The organic layer was washed with water and brine, dried over MgSO 4 and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane) to give bis(4-isobutylphenyl)-methyl 3-bromophenyl sulfide (20a) (1.60 g, 64.7%) as a colorless oil.
